We are recruiting @Perlmutter_CC ! Feel free to DM me for details! Gastrointestinal Medical Oncology Faculty Physician - focused at our NYU Langone Hospital – Long Island campus in Mineola NY. Fantastic opportunity to join growing program, including the new GI Cancer Center.
Shifting from surgery to chemoablation for low-grade #BladderCancer treatment. @KSMurrayUro@NYUUrology joins @zklaassen_md@GACancerCenter to discuss chemoablation with mitomycin (ZUSDURI™) for low-grade intermediate-risk #NMIBC. The discussion covers practical implementation details, including the gel formulation, catheter placement, and the six-week treatment course without maintenance therapy. #WatchNow > https://t.co/3CSYg3JCGi
🚨 In this week's episode Michael Morris from MSKCC joins Brian and Tom for an in-depth review of ARPI development across the spectrum of prostate cancer.
🍎 Apple Podcasts: https://t.co/7i5LrKpjUU
🎧Spotify: https://t.co/2cTzBkc62Z
Variant Histologies of Bladder Cancer - They are more like different types of music with distinct
- openers (neoadjuvant therapy)
- headliners (front line therapy)
Learn more ahead of #Uromigoslive25@Uromigos
ADT remodels the tumor microenvironment from immunologically cold to hot. Matthew Dallos, MD @MSKCancerCenter joins @AndreaMiyahira@PCFnews in this discussion of how androgen deprivation therapy reshapes the immune landscape in localized #ProstateCancer. #WatchNow > https://t.co/DFlGl0vZ9v
This was the date set in the end of year (2024) appropriations bill passed by the prior Congress and signed by President Biden. This new Congress was always going to have to provide for a statutory extension. We knew this in December. I’m confident Congress will act. Our seniors deserve it. But speak up and speak out out to your Reps and Senators. #telehealth #medtwitter #radonc
Everyone in academic medicine is hopeful the pause at NIH will be temporary. The research funding pause will affect post doctoral
researchers, technicians, and academic research efforts across the United States.
https://t.co/OWYKGALY4e
Dual action hormone therapy targeting two parts of the androgen receptor simultaneously shows tolerability and early efficacy in phase I trial. @alaccetti@MSKCancerCenter and @DrRanaMcKay@UCSanDiego discuss recent advancements in #mCRPC treatments > https://t.co/hqEpfHQs2b
We are pleased to announce the PCCTC-managed study of EPI-7386 in combination with enzalutamide in subjects with metastatic prostate cancer has entered phase 2. For more information visit: https://t.co/KlW3EYyvoO
ADT interruption in patients responding exceptionally to AR-pathway inhibitor in #mHSPC: A-DREAM. @AtishChoudhury and @CaPsurvivorship@DanaFarber discuss the right balance of treatment duration for patients with metastatic prostate cancer > https://t.co/adsrTa9GY1
Andrew Laccetti, MD, MS, at @MSKCancerCenter underscores “to date, androgen receptor (AR) pathway inhibitors either competitively antagonize the receptor via the ligand-binding domain or block androgen synthesis.” https://t.co/gKDDYBRDua @alaccetti#ESMO23